Latest Breaking News On - Development therapeutic areas - Page 1 : vimarsana.com

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

Pfizer and Astellas announce positive top-line results from Phase 3 EMBARK trial MARKHAM, ON, March 23, 2023 /CNW/ - Astellas Pharma Inc. , the parent company of Astellas Pharma Canada, Inc., has. | March 23, 2023

United statesChris boshoffKenji yasukawaAhsan arozullahAstellas pharma incAmerican society of clinical oncologyMedivation incAstellas incEuropean unionPfizer global product developmentHealth canadaHead of development therapeutic areasAstellas pharma canada incPharma incPharma canadaSenior vice president

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present detailed results from the Phase 3 GLOW.

New yorkUnited statesUnited kingdomKenji yasukawaAhsan arozullahRui hua xuManisha shahNational cancer instituteAmerican society of clinical oncologySun yat sen university cancer centerDepartment of medical oncologyEnd results programAstellas pharma incHead of development therapeutic areasGastrointestinal oncology programPrnewswire astellas pharma inc

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomKenji yasukawaAhsan arozullahRui hua xuManisha shahNational cancer instituteAmerican society of clinical oncologySun yat sen university cancer centerDepartment of medical oncologyAstellas pharma incEnd results programAstellasastellas pharma incHead of development therapeutic areasGastrointestinal oncology program

XTANDI Plus Leuprolide Enhances MFS in Non-Metastatic Prostate Cancer

XTANDI Plus Leuprolide Enhances MFS in Non-Metastatic Prostate Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Kenji yasukawaChris boshoffAhsan arozullahAstellas pharma incPfizer incHead of development therapeutic areasDrug administrationPfizer global product developmentAstellas pharmaChief development officerRare diseasePfizer global productSenior vice presidentDevelopment therapeutic areas

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

/PRNewswire/ Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive.

United statesKenji yasukawaChris boshoffAhsan arozullahAmerican society of clinical oncologyPrnewswire pfizer incDrug administrationPfizer global product developmentLab abnormalitiesAstellas incExchange commissionAstellas pharma incPfizer incEuropean unionHead of development therapeutic areasMedivation inc